Gain Therapeutics (GANX) Study Result summary

Study overview and objectives

• Phase I-B study of GT-02287 in Parkinson's disease patients, focusing on safety, tolerability, and exploratory biomarkers, is ongoing in Australia with a 90-day dosing period and a nine-month extension phase.

• 21 participants enrolled, mostly early to mid-stage Parkinson's, with a mix of idiopathic and GBA1 mutation carriers; majority on standard Parkinson's medications.

• Main objectives include assessing safety, tolerability, pharmacokinetics, and target engagement, with biomarker and clinical endpoint data to be analyzed and reported in late Q4.

Mechanism of action and preclinical insights

• GT-02287 targets glucocerebrosidase (GCase), stabilizing its structure and function, supporting lysosomal and mitochondrial health, and reducing toxic substrate accumulation.

• Preclinical models show GT-02287 improves neural protection, lysosomal and mitochondrial function, and reduces alpha-synuclein aggregation.

Biomarker landscape in Parkinson's disease

• Recent advances include the seed amplification assay for alpha-synuclein, enabling earlier and more precise disease detection.

• Biomarkers are critical for stratifying patients, tracking disease progression, and improving trial efficiency; efforts are ongoing to develop quantitative and imaging biomarkers.

• The field is moving toward precision medicine, integrating genetic, biochemical, and digital biomarkers for targeted trials.